NASDAQ:OPNT - Opiant Pharmaceuticals Stock Price, Forecast & News

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) announced its quarterly earnings data on Tuesday, November, 12th. The technology company reported $1.97 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.10 by $1.87. The technology company earned $20.64 million during the quarter, compared to analysts' expectations of $5.73 million. Opiant Pharmaceuticals had a negative return on equity of 7.39% and a net margin of 24.16%. View Opiant Pharmaceuticals' Earnings History.

Opiant Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Opiant Pharmaceuticals.

Opiant Pharmaceuticals will be holding an earnings conference call on Wednesday, March 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

1 brokerages have issued 1-year price targets for Opiant Pharmaceuticals' shares. Their forecasts range from $42.00 to $42.00. On average, they anticipate Opiant Pharmaceuticals' share price to reach $42.00 in the next twelve months. This suggests a possible upside of 247.4% from the stock's current price. View Analyst Price Targets for Opiant Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opiant Pharmaceuticals.

Media stories about OPNT stock have been trending somewhat negative on Wednesday, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Opiant Pharmaceuticals earned a daily sentiment score of -1.2 on InfoTrie's scale. They also assigned media stories about the technology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Opiant Pharmaceuticals.

Opiant Pharmaceuticals saw a decrease in short interest in February. As of February 14th, there was short interest totalling 7,300 shares, a decrease of 52.0% from the January 30th total of 15,200 shares. Based on an average trading volume of 17,000 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.2% of the shares of the company are short sold. View Opiant Pharmaceuticals' Current Options Chain.

Some companies that are related to Opiant Pharmaceuticals include Mountain Province Diamonds (MPVD), Jaguar Mining (JAGGF), Fission Uranium (FCUUF), Rubicon Minerals (RBYCF), Amerigo Resources (ARREF), Atlatsa Resources (ATLRF), Wealth Minerals (WMLLF), Royal Standard Minerals Inc USA (RYSMF), Santa Fe Gold (SFEG), Pacific Booker Minerals (PBMLF), Bullfrog Gold (BFGC), Alderon Iron Ore (AXXDF), US Gold (USAU), Quantum Materials (QTMM) and Silver Bull Resources (SVBL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include Cara Therapeutics (CARA), AcelRx Pharmaceuticals (ACRX), Canopy Growth (CGC), Corbus Pharmaceuticals (CRBP), Cronos Group (CRON), Vodafone Group (VOD), Synchrony Financial (SYF), Cyberark Software (CYBR), Sangamo Therapeutics (SGMO) and Xilinx (XLNX).

Opiant Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.00%), Perritt Capital Management Inc. (0.88%), Wedge Capital Management L L P NC (0.55%), Advisor Group Inc. (0.16%), Advisory Services Network LLC (0.15%) and TCI Wealth Advisors Inc. (0.08%). Company insiders that own Opiant Pharmaceuticals stock include Ann L Macdougall, David D O'toole, Gabrielle Alison Silver, Michael Sinclair, Phil Skolnick, Roger Crystal and Thomas T Thomas. View Institutional Ownership Trends for Opiant Pharmaceuticals.

OPNT stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC. Company insiders that have sold Opiant Pharmaceuticals company stock in the last year include Michael Sinclair, Phil Skolnick and Roger Crystal. View Insider Buying and Selling for Opiant Pharmaceuticals.

OPNT stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Advisory Services Network LLC, TCI Wealth Advisors Inc., Tobias Financial Advisors Inc., Perritt Capital Management Inc. and Advisor Group Inc.. Company insiders that have bought Opiant Pharmaceuticals stock in the last two years include Ann L Macdougall, David D O'toole and Gabrielle Alison Silver. View Insider Buying and Selling for Opiant Pharmaceuticals.

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OPNT stock can currently be purchased for approximately $12.09.

Opiant Pharmaceuticals has a market capitalization of $49.51 million and generates $13.98 million in revenue each year. The technology company earns $-21,190,000.00 in net income (profit) each year or ($7.10) on an earnings per share basis. Opiant Pharmaceuticals employs 16 workers across the globe.View Additional Information About Opiant Pharmaceuticals.

The official website for Opiant Pharmaceuticals is http://www.opiant.com/.

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]